EpiMetal: an Open-source Graphical Web Browser Tool for Easy Statistical Analyses in Epidemiology and Metabolomics

Overview

Journal Int J Epidemiol

Specialty Public Health

Date 2020 Jan 17

PMID 31943015

Citations 2

Authors

Jussi Ekholm

Pauli Ohukainen

Antti J Kangas

Johannes Kettunen

Qin Wang

Mari Karsikas

Anmar A Khan

Bronwyn A Kingwell

Mika Kahonen

Terho Lehtimaki

Olli T Raitakari

Marjo-Riitta Jarvelin

Peter J Meikle

Mika Ala-Korpela

Affiliations

Soon will be listed here.

Abstract

Motivation: An intuitive graphical interface that allows statistical analyses and visualizations of extensive data without any knowledge of dedicated statistical software or programming.

Implementation: EpiMetal is a single-page web application written in JavaScript, to be used via a modern desktop web browser.

General Features: Standard epidemiological analyses and self-organizing maps for data-driven metabolic profiling are included. Multiple extensive datasets with an arbitrary number of continuous and category variables can be integrated with the software. Any snapshot of the analyses can be saved and shared with others via a www-link. We demonstrate the usage of EpiMetal using pilot data with over 500 quantitative molecular measures for each sample as well as in two large-scale epidemiological cohorts (N >10 000).

Availability: The software usage exemplar and the pilot data are open access online at [http://EpiMetal.computationalmedicine.fi]. MIT licensed source code is available at the Github repository at [https://github.com/amergin/epimetal].

Citing Articles

Clinical and biochemical associations of urinary metabolites: quantitative epidemiological approach on renal-cardiometabolic biomarkers.

Li T, Ihanus A, Ohukainen P, Jarvelin M, Kahonen M, Kettunen J Int J Epidemiol. 2023; 53(1).

PMID: 38030573 PMC: 10859141. DOI: 10.1093/ije/dyad162.

New software tools, databases, and resources in metabolomics: updates from 2020.

Misra B Metabolomics. 2021; 17(5):49.

PMID: 33977389 PMC: 8112213. DOI: 10.1007/s11306-021-01796-1.

References

Lithovius R, Toppila I, Harjutsalo V, Forsblom C, Groop P, Makinen V . Data-driven metabolic subtypes predict future adverse events in individuals with type 1 diabetes. Diabetologia. 2017; 60(7):1234-1243. DOI: 10.1007/s00125-017-4273-8. View

Schaefer E, Levy R, Anderson D, Danner R, BREWER Jr H, Blackwelder W . Plasma-triglycerides in regulation of H.D.L.-cholesterol levels. Lancet. 1978; 2(8086):391-3. DOI: 10.1016/s0140-6736(78)91863-9. View

Makinen V, Forsblom C, Thorn L, Waden J, Gordin D, Heikkila O . Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes. 2008; 57(9):2480-7. PMC: 2518500. DOI: 10.2337/db08-0332. View

Makinen V, Kangas A, Soininen P, Wurtz P, Groop P, Ala-Korpela M . Metabolic phenotyping of diabetic nephropathy. Clin Pharmacol Ther. 2013; 94(5):566-9. DOI: 10.1038/clpt.2013.158. View

Weir J, Wong G, Barlow C, Greeve M, Kowalczyk A, Almasy L . Plasma lipid profiling in a large population-based cohort. J Lipid Res. 2013; 54(10):2898-908. PMC: 3770102. DOI: 10.1194/jlr.P035808. View

Wurtz P, Kangas A, Soininen P, Lawlor D, Davey Smith G, Ala-Korpela M . Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies. Am J Epidemiol. 2017; 186(9):1084-1096. PMC: 5860146. DOI: 10.1093/aje/kwx016. View

Gao S, Mutter S, Casey A, Makinen V . Numero: a statistical framework to define multivariable subgroups in complex population-based datasets. Int J Epidemiol. 2018; 48(2):369-374. DOI: 10.1093/ije/dyy113. View

Wurtz P, Wang Q, Soininen P, Kangas A, Fatemifar G, Tynkkynen T . Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase. J Am Coll Cardiol. 2016; 67(10):1200-1210. PMC: 4783625. DOI: 10.1016/j.jacc.2015.12.060. View

Straznicky N, Lambert E, Nestel P, McGrane M, Dawood T, Schlaich M . Sympathetic neural adaptation to hypocaloric diet with or without exercise training in obese metabolic syndrome subjects. Diabetes. 2009; 59(1):71-9. PMC: 2797947. DOI: 10.2337/db09-0934. View

10.

Huynh K, Barlow C, Jayawardana K, Weir J, Mellett N, Cinel M . High-Throughput Plasma Lipidomics: Detailed Mapping of the Associations with Cardiometabolic Risk Factors. Cell Chem Biol. 2018; 26(1):71-84.e4. DOI: 10.1016/j.chembiol.2018.10.008. View

11.

Straznicky N, Grima M, Sari C, Eikelis N, Lambert G, Nestel P . A randomized controlled trial of the effects of pioglitazone treatment on sympathetic nervous system activity and cardiovascular function in obese subjects with metabolic syndrome. J Clin Endocrinol Metab. 2014; 99(9):E1701-7. DOI: 10.1210/jc.2014-1976. View

12.

Khan A, Mundra P, Straznicky N, Nestel P, Wong G, Tan R . Weight Loss and Exercise Alter the High-Density Lipoprotein Lipidome and Improve High-Density Lipoprotein Functionality in Metabolic Syndrome. Arterioscler Thromb Vasc Biol. 2017; 38(2):438-447. DOI: 10.1161/ATVBAHA.117.310212. View

13.

Kumpula L, Makela S, Makinen V, Karjalainen A, Liinamaa J, Kaski K . Characterization of metabolic interrelationships and in silico phenotyping of lipoprotein particles using self-organizing maps. J Lipid Res. 2009; 51(2):431-9. PMC: 2803246. DOI: 10.1194/jlr.D000760. View

14.

Mundra P, Shaw J, Meikle P . Lipidomic analyses in epidemiology. Int J Epidemiol. 2016; 45(5):1329-1338. DOI: 10.1093/ije/dyw112. View

15.

Soininen P, Kangas A, Wurtz P, Suna T, Ala-Korpela M . Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet. 2015; 8(1):192-206. DOI: 10.1161/CIRCGENETICS.114.000216. View

16.

Makinen V, Tynkkynen T, Soininen P, Peltola T, Kangas A, Forsblom C . Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study). J Proteome Res. 2011; 11(3):1782-90. DOI: 10.1021/pr201036j. View

17.

Ala-Korpela M, Davey Smith G . Metabolic profiling-multitude of technologies with great research potential, but (when) will translation emerge?. Int J Epidemiol. 2016; 45(5):1311-1318. PMC: 5100630. DOI: 10.1093/ije/dyw305. View

18.

Sliz E, Kettunen J, Holmes M, Williams C, Boachie C, Wang Q . Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment. Circulation. 2018; 138(22):2499-2512. PMC: 6254781. DOI: 10.1161/CIRCULATIONAHA.118.034942. View

19.

Kumpula L, Kumpula J, Taskinen M, Jauhiainen M, Kaski K, Ala-Korpela M . Reconsideration of hydrophobic lipid distributions in lipoprotein particles. Chem Phys Lipids. 2008; 155(1):57-62. DOI: 10.1016/j.chemphyslip.2008.06.003. View

20.

Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J . UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015; 12(3):e1001779. PMC: 4380465. DOI: 10.1371/journal.pmed.1001779. View